Microsofts Anthropic Partnership May Unlock 43 Billion Azure Revenue by 2030 HSBC Suggests Arm Holdings Reaches Record High on Analyst Outlook for Fivefold Profit Growth by 2030 Barclays Posts 18 Profit Increase Upgrades FullYear Income Forecast US Job Market Weakens in October and November Federal Data Shows EU Plastic Bottle Cap Regulation Highlights Divides Over Regulatory Approach LSEG Reports Income Growth Driven by Tradeweb Performance D Q1 2026 Earnings EPS Beats Estimates as Regulated Earnings Support Growth BWMX Q1 2026 Earnings EPS Misses Estimates Despite Positive Stock Reaction Birchtech Corp BCHT Q1 2026 Earnings EPS Misses Estimates as Loss Widens Stock Rises 116 Aprea Therapeutics Inc APRE Q1 2026 Earnings NarrowerThanExpected Loss Highlights Cost Discipline Amid Clinical Progress Edgewise Therapeutics Inc EWTX Q1 2026 Earnings Narrowerthanexpected loss underscores disciplined RD execution Hologic HOLX Q1 2026 Earnings EPS Misses Expectations Amidst Flat Stock Reaction BUD Stock Slides 177 Technical Levels and Sector Context CarPartscom PRTS Edges Higher as Stock Consolidates Near Key Support Nuveen Pennsylvania Quality Municipal Income Fund NQP Holds Steady Amid Modest Uptick UTStarcom Holdings UTSI Surges 575 as Shares Test Key Resistance at 298 Adicet Bio Inc ACET Rises 165 as Biotech Sector Shows Mixed Signals Suncor Energy SU Retreats 243 as Selling Pressure Builds Toward Support PureCycle Technologies PCTTU Holds Steady at 620 Amid Consolidation Phase Creative Medical Technology Holdings CELZ Edges Higher as Biotech Stock Tests Resistance Hologic Inc HOLX Holds Steady at 7601 Consolidation Between Key Support and Resistance NexPoint Residential Trust NXRT Slides Slightly While Holding Above Key Support Levels Treasure Global Inc TGL Gains 384 Support and Resistance Levels in Focus Helios Underwriting Schedules June 22 Annual General Meeting Confirms Dividend Payment Dates Compass Therapeutics Q1 2026 Earnings NarrowerThanExpected Loss Supports Biotechs Pipeline Progress TransCode Therapeutics RNAZ Surges 2 as Biotech Stock Tests Key Resistance at 655